Identity
- Security key
- 23449
- Ticker
- VRAX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2022-07-21
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- VRAX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $2,215,626.64
- Shares outstanding (class)
- 796,937
- Shares outstanding (weighted)
- 796,988
- SIC
- —
- Employees
- 26
- Location
- —
- Homepage
- https://www.viraxbiolabs.com
- Description
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Market cap and share counts drift.